Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Surface Logix Commences Phase 2a Clinical Trial Of Slx-2101 In Raynaud's Disease


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 06 July 2007 - 07:46 AM

Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease. SLx-2101 is a novel, long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's. Digital50. Surface Logix Inc. 06/28/07. (Also see: Raynaud's Treatments, and Clinical Trials)